NeOnc Technologies (NTHI)

Executive Summary

NeOnc Technologies is a clinical-stage life sciences company pioneering a novel intranasal drug delivery platform designed to bypass the blood-brain barrier (BBB) for the treatment of brain cancers and other central nervous system (CNS) diseases. The company's proprietary technology enables direct delivery of therapeutics to the brain, addressing a critical unmet need in oncology and neurology where the BBB severely limits treatment options. NeOnc's lead candidate, NEO100 (intranasal perillyl alcohol), is currently in Phase 2 clinical trials for recurrent glioblastoma, a highly aggressive brain cancer with poor prognosis. The platform's potential extends beyond oncology to neurodegenerative diseases such as Alzheimer's and Parkinson's, offering a versatile approach to CNS drug delivery. Founded in 2015 and headquartered in Los Angeles, NeOnc is privately held with an estimated valuation of ~$164 million and approximately 25.3 million shares outstanding. NeOnc's differentiated intranasal delivery system could transform the CNS therapeutic landscape by enabling non-invasive, targeted drug administration. The company's near-term focus is on advancing NEO100 through Phase 2 development, with a data readout anticipated in the second half of 2026. Success in recurrent glioblastoma would not only provide a new treatment option but also validate the platform for broader CNS applications. Additionally, NeOnc may pursue partnerships to expand its pipeline into other indications, leveraging its technology to address high-value CNS targets. With a clear clinical path and a platform with significant upside potential, NeOnc represents an intriguing opportunity in the biotech space, albeit with inherent clinical-stage risks.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 topline data for NEO100 in recurrent glioblastoma60% success
• Q4 2026Initiation of Phase 2 trial for NEO100 in brain metastases70% success
• TBDStrategic partnership or licensing deal for CNS delivery platform30% success